580 related articles for article (PubMed ID: 11753825)
1. Risk factors for development of tuberculosis after isoniazid chemoprophylaxis in human immunodeficiency virus-infected patients.
Casado JL; Moreno S; Fortún J; Antela A; Quereda C; Navas E; Moreno A; Dronda F
Clin Infect Dis; 2002 Feb; 34(3):386-9. PubMed ID: 11753825
[TBL] [Abstract][Full Text] [Related]
2. Isoniazid preventive therapy in human immunodeficiency virus-infected persons. Long-term effect on development of tuberculosis and survival.
Moreno S; Miralles P; Diaz MD; Baraia J; Padilla B; Berenguer J; Alberdi JC
Arch Intern Med; 1997 Aug 11-25; 157(15):1729-34. PubMed ID: 9250234
[TBL] [Abstract][Full Text] [Related]
3. Effect of isoniazid chemoprophylaxis on HIV-related mycobacterial disease.
Graham NM; Galai N; Nelson KE; Astemborski J; Bonds M; Rizzo RT; Sheeley L; Vlahov D
Arch Intern Med; 1996 Apr; 156(8):889-94. PubMed ID: 8774208
[TBL] [Abstract][Full Text] [Related]
4. A controlled trial of isoniazid in persons with anergy and human immunodeficiency virus infection who are at high risk for tuberculosis. Terry Beirn Community Programs for Clinical Research on AIDS.
Gordin FM; Matts JP; Miller C; Brown LS; Hafner R; John SL; Klein M; Vaughn A; Besch CL; Perez G; Szabo S; El-Sadr W
N Engl J Med; 1997 Jul; 337(5):315-20. PubMed ID: 9233868
[TBL] [Abstract][Full Text] [Related]
5. Reduction of clinical tuberculosis in HIV-infected males with isoniazid prophylaxis.
Alaei K; Alaei A; Mansouri D
East Mediterr Health J; 2002 Nov; 8(6):754-7. PubMed ID: 15568452
[TBL] [Abstract][Full Text] [Related]
6. Active tuberculosis in individuals infected with human immunodeficiency virus after isoniazid prophylaxis.
Fitzgerald DW; Morse MM; Pape JW; Johnson WD
Clin Infect Dis; 2000 Dec; 31(6):1495-7. PubMed ID: 11096020
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of isoniazid treatment for latent tuberculosis infection among human immunodeficiency virus (HIV)-infected and HIV-uninfected injection drug users in methadone programs.
Scholten JN; Driver CR; Munsiff SS; Kaye K; Rubino MA; Gourevitch MN; Trim C; Amofa J; Seewald R; Highley E; Fujiwara PI
Clin Infect Dis; 2003 Dec; 37(12):1686-92. PubMed ID: 14689352
[TBL] [Abstract][Full Text] [Related]
8. Influence of the human immunodeficiency virus in the incidence of tuberculosis in a cohort of intravenous drug users: effectiveness of anti-tuberculosis chemoprophylaxis.
Jansà JM; Serrano J; Caylà JA; Vidal R; Ocaña I; Español T
Int J Tuberc Lung Dis; 1998 Feb; 2(2):140-6. PubMed ID: 9580481
[TBL] [Abstract][Full Text] [Related]
9. Isoniazid TB prophylaxis effective in drug users with HIV.
J Int Assoc Physicians AIDS Care; 1996 Jun; 2(6):51. PubMed ID: 11363698
[TBL] [Abstract][Full Text] [Related]
10. Effect of isoniazid prophylaxis on incidence of active tuberculosis among Thai HIV-infected individuals.
Saenghirunvattana S
J Med Assoc Thai; 1996 May; 79(5):285-7. PubMed ID: 8708519
[TBL] [Abstract][Full Text] [Related]
11. Prospective randomized control trial of isoniazid chemoprophylaxis during renal replacement therapy.
Vikrant S; Agarwal SK; Gupta S; Bhowmik D; Tiwari SC; Dash SC; Guleria S; Mehta SN
Transpl Infect Dis; 2005; 7(3-4):99-108. PubMed ID: 16390397
[TBL] [Abstract][Full Text] [Related]
12. The impact of isoniazid preventive therapy and antiretroviral therapy on tuberculosis in children infected with HIV in a high tuberculosis incidence setting.
Frigati LJ; Kranzer K; Cotton MF; Schaaf HS; Lombard CJ; Zar HJ
Thorax; 2011 Jun; 66(6):496-501. PubMed ID: 21460373
[TBL] [Abstract][Full Text] [Related]
13. Randomised controlled trial of isoniazid preventive therapy in South African adults with advanced HIV disease.
Mohammed A; Myer L; Ehrlich R; Wood R; Cilliers F; Maartens G
Int J Tuberc Lung Dis; 2007 Oct; 11(10):1114-20. PubMed ID: 17945069
[TBL] [Abstract][Full Text] [Related]
14. Rifampicin plus pyrazinamide versus isoniazid for treating latent tuberculosis infection: a meta-analysis.
Gao XF; Wang L; Liu GJ; Wen J; Sun X; Xie Y; Li YP
Int J Tuberc Lung Dis; 2006 Oct; 10(10):1080-90. PubMed ID: 17044199
[TBL] [Abstract][Full Text] [Related]
15. Missed opportunities for prevention of tuberculosis among persons with HIV infection--selected locations, United States, 1996-1997.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2000 Aug; 49(30):685-7. PubMed ID: 10947056
[TBL] [Abstract][Full Text] [Related]
16. Preventing latent tuberculosis among HIV-infected patients: efficacious and effective, yet inefficient?
Rieder HL
Clin Infect Dis; 2007 Jan; 44(1):103-4. PubMed ID: 17143824
[No Abstract] [Full Text] [Related]
17. Tuberculosis with human immunodeficiency virus infection.
Cherian T; Verghese VP
Indian J Pediatr; 2000 Feb; 67(2 Suppl):S47-52. PubMed ID: 11129908
[TBL] [Abstract][Full Text] [Related]
18. TB prevention in HIV clinics in New York City.
Sackoff JE; Torian LV; Frieden TR
Int J Tuberc Lung Dis; 2001 Feb; 5(2):123-8. PubMed ID: 11258505
[TBL] [Abstract][Full Text] [Related]
19. [Primary chemoprevention of tuberculosis in HIV-infected patients in non-industrialized countries].
Anglaret X; Dabis F; Batungwanayo J; Perronne C; Taelman H; Bonard D; Sylla-Koko F; Leroy V; Van de Perre P; Vildé JL; Salamon R
Sante; 1997; 7(2):89-94. PubMed ID: 9273126
[TBL] [Abstract][Full Text] [Related]
20. Relapse of tuberculosis after treatment in human immunodeficiency virus-infected patients.
Pulido F; Peña JM; Rubio R; Moreno S; González J; Guijarro C; Costa JR; Vázquez JJ
Arch Intern Med; 1997 Jan; 157(2):227-32. PubMed ID: 9009982
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
